AI news
Vysioneer reports live use of AI assessment in an oncology trial
Vysioneer says its VTrial platform has been deployed prospectively in an active, pharma-sponsored oncology trial to help assess treatment response using AI-assisted RECIST 1.1. That moves the vendor-reported use beyond a retrospective test into an ongoing clinical workflow. The issuer cites an ESMO abstract, but this announcement does not establish a treatment benefit or clinical outcome.
Primary source · Vysioneer · October 20, 2026
Opens Vysioneer in a new tab. Read it there before you rely on the summary above.
Read the original
Free, email only
Unlock the full brief free.
- What to check before you trust this story, written down
- Each verified source, with why it matters and who published it
- A note whenever a source has been withdrawn
- Thirty days of stories to browse, not seven
Continuing subscribes the email on that account to Work Worth Doing, my newsletter, the same as the form below, and unlocks every free tool in this browser. We only receive your email address. Unsubscribe in one click.